Inflammatory markers in population studies of aging

Ageing Research Reviews

Volumn 10, Issue 3, 2011, Pages 319-329

  Singh, Tushar ^a   Newman, Anne B ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Disability; Inflammatory markers; Mortality

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; SEX HORMONE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

AGING; BREAST CANCER; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DEPRESSION; DISABILITY; EXERCISE; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; LIPID DIET; LUNG CANCER; LYMPHOMA; MENTAL DETERIORATION; MORTALITY; MULTIPLE MYELOMA; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIODONTAL DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SMOKING; WALKING DIFFICULTY;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; INFLAMMATION; NEOPLASMS; RISK FACTORS;

EID: 79955973916     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.11.002     Document Type: Review

References (165)

1. Aggarwal B.B., Shishodia S., et al. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 2006, 72(11):1605-1621.
2. Anderson J.L., Allen Maycock C.A., et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am. J. Cardiol. 2004, 94(10):1255-1259.
3. Arnson Y., Shoenfeld Y., et al. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J. Autoimmun. 2010, 34(3):J258-J265.
4. Aviles R.J., Martin D.O., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108(24):3006-3010.
5. Barbieri M., Ferrucci L., et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am. J. Physiol. Endocrinol. Metab. 2003, 284(3):E481-E487.
6. Barzilay J.I., Abraham L., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001, 50(10):2384-2389.
7. Basaria S., Coviello A.D., et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 2010, 363(2):109-122.
8. Beasley L.E., Koster A., et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring) 2009, 17(5):1062-1069.
9. Beckett N., Nunes M., et al. Is it advantageous to lower cholesterol in the elderly hypertensive?. Cardiovasc. Drugs Ther. 2000, 14(4):397-405.
10. Bermudez E.A., Rifai N., et al. Relation between markers of systemic vascular inflammation and smoking in women. Am. J. Cardiol. 2002, 89(9):1117-1119.
11. Bertoni A.G., Burke G.L., et al. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2010, 33(4):804-810.
12. Birmann B.M., Tamimi R.M., et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol. Biomarkers Prev. 2009, 18(1):282-288.
13. Bretz W.A., Weyant R.J., et al. Systemic inflammatory markers, periodontal diseases, and periodontal infections in an elderly population. J. Am. Geriatr. Soc. 2005, 53(9):1532-1537.
14. Bruunsgaard H., Skinhoj P., et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin. Exp. Immunol. 2000, 121(2):255-260.
15. Cao J.J., Arnold A.M., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007, 116(1):32-38.
16. Cartier A., Cote M., et al. Age-related differences in inflammatory markers in men: contribution of visceral adiposity. Metabolism 2009, 58(10):1452-1458.
17. Cauley J.A., Danielson M.E., et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J. Bone Miner. Res. 2007, 22(7):1088-1095.
18. Cesari M., Onder G., et al. C-reactive protein and lipid parameters in older persons aged 80 years and older. J. Nutr. Health Aging 2009, 13(7):587-593.
19. Cesari M., Penninx B.W., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108(19):2317-2322.
20. Cesari M., Penninx B.W., et al. Inflammatory markers and cardiovascular disease (The Health Aging and Body Composition [Health ABC] Study). Am. J. Cardiol. 2003, 92(5):522-528.
21. Cesari M., Penninx B.W., et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J. Gerontol. A: Biol. Sci. Med. Sci. 2004, 59(3):242-248.
22. Chung H.Y., Cesari M., et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res. Rev. 2009, 8(1):18-30.
23. Cohen H.J., Harris T., et al. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am. J. Med. 2003, 114(3):180-187.
24. Cohen H.J., Pieper C.F., et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J. Gerontol. A: Biol. Sci. Med. Sci. 1997, 52(4):M201-M208.
25. Comijs H.C., Dik M.G., et al. The course of cognitive decline in older persons: results from the longitudinal aging study amsterdam. Dement. Geriatr. Cogn. Disord. 2004, 17(3):136-142.
26. Cruz-Jentoft A.J., Landi F., et al. Understanding sarcopenia as a geriatric syndrome. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13(1):1-7.
27. Curat C.A., Miranville A., et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004, 53(5):1285-1292.
28. Cushman M., Arnold A.M., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005, 112(1):25-31.
29. Das I. Raised C-reactive protein levels in serum from smokers. Clin. Chim. Acta 1985, 153(1):9-13.
30. de Lorgeril M., Salen P., et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch. Intern. Med. 2010, 170(12):1032-1036.
31. Dehghan A., Kardys I., et al. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 2007, 56(3):872-878.
32. DeRijk R., Michelson D., et al. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J. Clin. Endocrinol. Metab. 1997, 82(7):2182-2191.
33. Ding C., Parameswaran V., et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J. Clin. Endocrinol. Metab. 2008, 93(5):1952-1958.
34. Elosua R., Bartali B., et al. Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: the InCHIANTI study. J. Gerontol. A: Biol. Sci. Med. Sci. 2005, 60(6):760-767.
35. Engelhart M.J., Geerlings M.I., et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch. Neurol. 2004, 61(5):668-672.
36. Erlinger T.P., Platz E.A., et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291(5):585-590.
37. Ershler W.B., Keller E.T. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 2000, 51:245-270.
38. Ershler W.B., Sun W.H., et al. The role of interleukin-6 in certain age-related diseases. Drugs Aging 1994, 5(5):358-365.
39. Ershler W.B., Sun W.H., et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993, 12(4):225-230.
40. Esposito K., Marfella R., et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292(12):1440-1446.
41. Fagiolo U., Cossarizza A., et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 1993, 23(9):2375-2378.
42. Ferrucci L., Corsi A., et al. The origins of age-related proinflammatory state. Blood 2005, 105(6):2294-2299.
43. Ferrucci L., Harris T.B., et al. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr. Soc. 1999, 47(6):639-646.
44. Ferrucci L., Penninx B.W., et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J. Am. Geriatr. Soc. 2002, 50(12):1947-1954.
45. Ferrucci L., Semba R.D., et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010, 115(18):3810-3816.
46. Festa A., D'Agostino R., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51(4):1131-1137.
47. Figaro M.K., Kritchevsky S.B., et al. Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care 2006, 29(9):2039-2045.
48. Fried L.P., Tangen C.M., et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A: Biol. Sci. Med. Sci. 2001, 56(3):M146-M156.
49. Fried L.P., Xue Q.L., et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(10):1049-1057.
50. Fried S.K., Bunkin D.A., et al. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998, 83(3):847-850.
51. Fulop T., Larbi A., et al. Aging, frailty and age-related diseases. Biogerontology 2010, 11(5):547-563.
52. Geffken D.F., Cushman M., et al. Association between physical activity and markers of inflammation in a healthy elderly population. Am. J. Epidemiol. 2001, 153(3):242-250.
53. Goronzy J.J., Weyand C.M. Cytokines in giant-cell arteritis. Cleve Clin. J. Med. 2002, 69(Suppl. 2):SII91-SII94.
54. Grimm R.H., Neaton J.D., et al. Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 1985, 254(14):1932-1937.
55. Haider A.W., Roubenoff R., et al. Monocyte cytokine production, systemic inflammation and cardiovascular disease in very elderly men and women: the Framingham Heart Study. Eur. J. Cardiovasc. Prev. Rehabil. 2004, 11(3):214-215.
56. Harris T.B., Ferrucci L., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 1999, 106(5):506-512.
57. Heikkila K., Ebrahim S., et al. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur. J. Cancer 2008, 44(7):937-945.
58. Heikkila K., Harris R., et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009, 20(1):15-26.
59. Howren M.B., Lamkin D.M., et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71(2):171-186.
60. Hsu F.C., Kritchevsky S.B., et al. Association between inflammatory components and physical function in the health, aging, and body composition study: a principal component analysis approach. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(5):581-589.
61. Hu F.B., Meigs J.B., et al. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53(3):693-700.
62. Hubbard R.E., O'Mahony M.S., et al. Inflammation and frailty measures in older people. J. Cell. Mol. Med. 2009, 13(9B):3103-3109.
63. Il'yasova D., Colbert L.H., et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 2005, 14(10):2413-2418.
64. Ioannidou E., Malekzadeh T., et al. Effect of periodontal treatment on serum C-reactive protein levels: a systematic review and meta-analysis. J. Periodontol. 2006, 77(10):1635-1642.
65. Jenny N.S., Yanez N.D., et al. Inflammation biomarkers and near-term death in older men. Am. J. Epidemiol. 2007, 165(6):684-695.
66. Jilka R.L., Hangoc G., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257(5066):88-91.
67. Kalogeropoulos A., Georgiopoulou V., et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J. Am. Coll. Cardiol. 2010, 55(19):2129-2137.
68. Kania D.M., Binkley N., et al. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J. Am. Geriatr. Soc. 1995, 43(3):236-239.
69. Kapoor D., Clarke S., et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 2007, 156(5):595-602.
70. Kaul S., Morrissey R.P., et al. By Jove! What is a clinician to make of JUPITER?. Arch. Intern. Med. 2010, 170(12):1073-1077.
71. Keller E.T., Chang C., et al. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J. Biol. Chem. 1996, 271(42):26267-26275.
72. Kern P.A., Ranganathan S., et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280(5):E745-E751.
73. Khosla S., Peterson J.M., et al. Circulating cytokine levels in osteoporotic and normal women. J. Clin. Endocrinol. Metab. 1994, 79(3):707-711.
74. Kim S., Keku T.O., et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 2008, 68(1):323-328.
75. Kishimoto T. IL-6: from its discovery to clinical applications. Int. Immunol. 2010, 22(5):347-352.
76. Klimiuk P.A., Sierakowski S., et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin. Exp. Rheumatol. 2003, 21(1):63-69.
77. Lang T., Streeper T., et al. Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos. Int. 2010, 21(4):543-559.
78. Lee C.C., Adler A.I., et al. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009, 52(6):1040-1047.
79. Lee C.G., Carr M.C., et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J. Clin. Endocrinol. Metab. 2009, 94(4):1104-1110.
80. Leng S.X., Hung W., et al. White blood cell counts, insulin-like growth factor-1 levels, and frailty in community-dwelling older women. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(4):499-502.
81. Leng S.X., Xue Q.L., et al. Baseline total and specific differential white blood cell counts and 5-year all-cause mortality in community-dwelling older women. Exp. Gerontol. 2005, 40(12):982-987.
82. Leng S.X., Xue Q.L., et al. Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: results from the Women's Health and Aging Studies I. Exp. Gerontol. 2009, 44(8):511-516.
83. Leng S.X., Xue Q.L., et al. Inflammation and frailty in older women. J. Am. Geriatr. Soc. 2007, 55(6):864-871.
84. Libby P., Ridker P.M., et al. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
85. Liu S., Tinker L., et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. Arch. Intern. Med. 2007, 167(15):1676-1685.
86. Lu H., Ouyang W., et al. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4(4):221-233.
87. Madhok R., Crilly A., et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 1993, 52(3):232-234.
88. Maggio M., Basaria S., et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J. Clin. Endocrinol. Metab. 2006, 91(1):345-347.
89. Maggio M., Basaria S., et al. The relationship between testosterone and molecular markers of inflammation in older men. J. Endocrinol. Invest. 2005, 28(11 Suppl. Proceedings):116-119.
90. Maggio M., Guralnik J.M., et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A: Biol. Sci. Med. Sci. 2006, 61(6):575-584.
91. Malkin C.J., Pugh P.J., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 2004, 89(7):3313-3318.
92. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 1995, 332(5):305-311.
93. Martinez-Taboada V.M., Alvarez L., et al. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008, 44(2):207-220.
94. McDermott M.M., Guralnik J.M., et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am. Heart J. 2005, 150(2):276-281.
95. Mohamed-Ali V., Goodrick S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 1997, 82(12):4196-4200.
96. Montecucco F., Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin. Immunopathol. 2009, 31(1):127-142.
97. Mora S., Glynn R.J., et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010, 121(9):1069-1077.
98. Murabito J.M., Keyes M.J., et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis 2009, 203(2):509-514.
99. Nappo F., Esposito K., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J. Am. Coll. Cardiol. 2002, 39(7):1145-1150.
100. Nawawi H., Osman N.S., et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis 2003, 169(2):283-291.
101. Nelson H.D., Humphrey L.L., et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288(7):872-881.
102. Newman A.B., Sachs M.C., et al. Total and cause-specific mortality in the cardiovascular health study. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(12):1251-1261.
103. Nicklas B.J., Hsu F.C., et al. Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J. Am. Geriatr. Soc. 2008, 56(11):2045-2052.
104. Noack B., Genco R.J., et al. Periodontal infections contribute to elevated systemic C-reactive protein level. J. Periodontol. 2001, 72(9):1221-1227.
105. Paraskevas S., Huizinga J.D., et al. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J. Clin. Periodontol. 2008, 35(4):277-290.
106. Passeri G., Girasole G., et al. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology 1993, 133(2):822-828.
107. Payette H., Roubenoff R., et al. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study. J. Am. Geriatr. Soc. 2003, 51(9):1237-1243.
108. Pedersen B.K., Steensberg A., et al. Exercise and interleukin-6. Curr. Opin. Hematol. 2001, 8(3):137-141.
109. Penninx B.W., Kritchevsky S.B., et al. Inflammatory markers and incident mobility limitation in the elderly. J. Am. Geriatr. Soc. 2004, 52(7):1105-1113.
110. Penninx B.W., Kritchevsky S.B., et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol. Psychiatry 2003, 54(5):566-572.
111. Pfeilschifter J., Koditz R., et al. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 2002, 23(1):90-119.
112. Pickup J.C., Chusney G.D., et al. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000, 67(3):291-300.
113. Pierce B.L., Biggs M.L., et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009, 20(7):1193-1203.
114. Pottratz S.T., Bellido T., et al. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J. Clin. Invest. 1994, 93(3):944-950.
115. Pou K.M., Massaro J.M., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007, 116(11):1234-1241.
116. Pradhan A.D., Manson J.E., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286(3):327-334.
117. Pradhan A.D., Manson J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288(8):980-987.
118. Quist-Paulsen P. Statins and inflammation: an update. Curr. Opin. Cardiol. 2010, 25(4):399-405.
119. Ravaglia G., Forti P., et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol. Aging 2007, 28(12):1810-1820.
120. Ray A., Prefontaine K.E., et al. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 1994, 269(17):12940-12946.
121. Ray P., Ghosh S.K., et al. Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett. 1997, 409(1):79-85.
122. Reinisch W., Gasche C., et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am. J. Gastroenterol. 1999, 94(8):2156-2164.
123. Reuben D.B., Cheh A.I., et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J. Am. Geriatr. Soc. 2002, 50(4):638-644.
124. Reuben D.B., Judd-Hamilton L., et al. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J. Am. Geriatr. Soc. 2003, 51(8):1125-1130.
125. Ridker P.M., Cushman M., et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97(5):425-428.
126. Ridker P.M., Danielson E., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373(9670):1175-1182.
127. Robak T., Gladalska A., et al. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 1998, 7(5):347-353.
128. Rockwood K., Rockwood M.R., et al. Physiological redundancy in older adults in relation to the change with age in the slope of a frailty index. J. Am. Geriatr. Soc. 2010, 58(2):318-323.
129. Rodondi N., Marques-Vidal P., et al. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am. J. Epidemiol. 2010, 171(5):540-549.
130. Roubenoff R., Harris T.B., et al. Monocyte cytokine production in an elderly population: effect of age and inflammation. J. Gerontol. A: Biol. Sci. Med. Sci. 1998, 53(1):M20-M26.
131. Roubenoff R., Parise H., et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am. J. Med. 2003, 115(6):429-435.
132. Ruggiero C., Metter E.J., et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J. Am. Coll. Cardiol. 2007, 49(18):1841-1850.
133. Sakamoto Y., Harada T., et al. Tumor necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-kappa B activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J. Clin. Endocrinol. Metab. 2003, 88(2):730-735.
134. Sawada M., Suzumura A., et al. TNF alpha induces IL-6 production by astrocytes but not by microglia. Brain Res. 1992, 583(1-2):296-299.
135. Schaap L.A., Pluijm S.M., et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64(11):1183-1189.
136. Schaap L.A., Pluijm S.M., et al. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med. 2006, 119(6):e9-e17.
137. Schmidt R., Schmidt H., et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 2002, 52(2):168-174.
138. Schrager M.A., Metter E.J., et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J. Appl. Physiol. 2007, 102(3):919-925.
139. Siemes C., Visser L.E., et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 2006, 24(33):5216-5222.
140. Stallmach A., Giese T., et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int. J. Colorectal Dis. 2004, 19(4):308-315.
141. Stark J.R., Li H., et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int. J. Cancer 2009, 124(11):2683-2689.
142. Steensberg A., van Hall G., et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 2000, 529(Pt 1):237-242.
143. Suzuki T., Katz R., et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ. Heart Fail. 2008, 1(4):242-248.
144. Taaffe D.R., Harris T.B., et al. Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J. Gerontol. A: Biol. Sci. Med. Sci. 2000, 55(12):M709-M715.
145. Thorand B., Lowel H., et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch. Intern. Med. 2003, 163(1):93-99.
146. Tiemeier H., Hofman A., et al. Inflammatory proteins and depression in the elderly. Epidemiology 2003, 14(1):103-107.
147. Tracy R.P., Lemaitre R.N., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler. Thromb. Vasc. Biol. 1997, 17(6):1121-1127.
148. Trayhurn P., Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 2005, 33(Pt 5):1078-1081.
149. Tzoulaki I., Murray G.D., et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur. Heart J. 2007, 28(3):354-362.
150. Vasan R.S., Sullivan L.M., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107(11):1486-1491.
151. Visser M., Pahor M., et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J. Gerontol. A: Biol. Sci. Med. Sci. 2002, 57(5):M326-M332.
152. Walston J., McBurnie M.A., et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch. Intern. Med. 2002, 162(20):2333-2341.
153. Walston J.D., Matteini A.M., et al. Inflammation and stress-related candidate genes, plasma interleukin-6 levels, and longevity in older adults. Exp. Gerontol. 2009, 44(5):350-355.
154. Weaver J.D., Huang M.H., et al. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59(3):371-378.
155. Wei J., Xu H., et al. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 1992, 51(25):1953-1956.
156. Weisberg S.P., McCann D., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112(12):1796-1808.
157. Williams L.M., Lali F., et al. Rac mediates TNF-induced cytokine production via modulation of NF-kappaB. Mol. Immunol. 2008, 45(9):2446-2454.
158. Xing Z., Gauldie J., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 1998, 101(2):311-320.
159. Xu H., Barnes G.T., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112(12):1821-1830.
160. Yaffe K., Kanaya A., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292(18):2237-2242.
161. Yaffe K., Lindquist K., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61(1):76-80.
162. Zeyda M., Stulnig T.M. Obesity, inflammation, and insulin resistance-a mini-review. Gerontology 2009, 55(4):379-386.
163. Zhang S.M., Buring J.E., et al. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann. Intern. Med. 2005, 142(6):425-432.
164. Zheng S.X., Vrindts Y., et al. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas 1997, 26(1):63-71.
165. Zuliani G., Volpato S., et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis 2007, 192(2):384-390.